The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
04 October 2017 OptiBiotix Health plc ("OptiBiotix" or the "Company") Successful launch of LPLDL® and SlimBiome® products at Supply Side West 2017 OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol, and diabetes announces the successful launch of its SlimBiome® and LPLDL® products at Supply Side West in Las Vegas, on 27-28 September 2017. The exhibition provided the opportunity to connect with 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries. The event also created the opportunity to meet with senior executives from existing corporate partners and potential new corporate partners, as well as distributors from Europe, the USA and Asia. The Company recently obtained FDA registration for both its LPLDL® and SlimBiome® product ranges allowing it to present its products at Supply Side West as the first of a number of commercial steps to supply these functional ingredients to food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market. LPLDL® was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, whilst SlimBiome® was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia and the USA. Further updates will be provided as interest develops into commercial agreements but early outcomes from the exhibition include:- 1. Sacco have appointed Dr Lucio Lepera as Product Manager for LPLDL®. This is a significant financial commitment from Sacco, to support entry to the US probiotic market and extend the opportunities offered by LPLDL® into dairy applications to access the $35.5 billion probiotic dairy market. 2. Cereal Ingredients have incorporated SlimBiome® into their range of cereal based particulates and speciality ingredients. This technical innovation extends the application of SlimBiome® into bakery products (e.g. cookies, cakes and tortillas), breakfast cereals (puffs and flakes), crackers, toppings (e.g. salad, breakfast) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars. This significantly extends the scale of the opportunity beyond weight management into the nutraceutical, health and wellbeing industry sectors. Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. We are particularly pleased by the commitment shown by our partners who
Very bullish - sounds like next six months will see a step-change in profits
Optibiotix - It gets better still! Now 77p offer, last chance to buy at sub 80p! A conversation with Optibiotix (LSE:OPTI) boss Steve O Hara today forces us to clarify one point about yesterday’s deal with Tata. © © In that deal, Tata has agreed, subject to a pilot trial, to exclusively manufacture galacto-oligosaccharide produced by OptiBiotix’s LP-LDL® strain (LPGOS) for the use in food and Over The counter (OTC) products. LPGOS has been shown in gut models to:- i. Increase the growth and biological activity of OptiBiotix’s cholesterol reducing strain (LP-LDL®), leading to a threefold increase in the strains cholesterol lowering ability ii. Modify an individual’s existing microbiome reducing cholesterol by up 22% That is clearly great news as we explained yesterday. But hang on was not Optibiotix meant to be doing a deal with Tata on is Slimbiome weight loss product. What happened to that? Over to O’Hara who says: This is an additional deal to the one we announced last December for a different product. We now have 2 separate deals with Tata, one with their consumer team for Slimbiome, and one with their manufacturing group for our microbiome modulating sugars. So Steve what happened to the Slimbiome deal to help some of Tom Wnnifrith’s in-laws who could do with shedding a pound or two? Surely by now we should get news of launches, dates and expected sales volumes. The Indian market for weight loss is massive – obesity and issues such as diabetes are very real problems these days. The word from O’Hara is that we will get news soon. Yesterday we noted that the Tata deal announced then was ONE of the big name transactions we expected this autumn. It has seen the shares head up to 75p-77p. When the others are announced they will race ahead far higher. The stance is BUY AT UP TO 80P WITH A TARGET TO SELL OVER 100P+ AND THAT WILL NOT BE LONG IN COMING.
Falanx share price decline - not warranted: BUY and watch this space (soon) Shares in Falanx (LSE:FLX) have slipped and slipped most of the summer. The reality is – as we noted with Optibiotix (LSE:OPTI) the other day that sensible folks are sitting on beaches and this means that there is a bit of an absence of buyers. Well let us clarify there is certainly an absence of buyers for small cap stocks where there has been no news and Falanx fits that bill. But there has been a seller. Steven Myers used to own over 10%. His last TR1 showed him down to 4% and I would not be surprised if the next TR1 had him out altogether or below 3%. So a material seller and no buyers causes a slide and in nervous times a sliding share price sees a bit of panic selling, folks hitting stop losses and 8p+ becomes 5p-5.5p. Has there been any bad news? Not at all. Indeed as per our last update things are going very well indeed at Falanx. What one might say is what on earth are its retained brokers up to. It is all very well them making 5% commission on the last £2 million placing but ab retained broker should also be banging the drum in the secondary market at times like this. At the least they should be working to place folks like Myers out in an orderly manner. But maybe that is all a rather old fashioned view. Anyhow the word on the street is that the news drought is almost over. The shares are on a fundamental basis very cheap indeed. And if you can buy at 6p or less do so – the target to sell is 9p+
Optibiotix - we buy more shares for first time in two years, price is just wrong PUBLISHED: 16 Aug 2017 @ 14:24 Thanks for all the emails on Optibiotix (LSE:OPTI). We understand seeing the shares slide back to 53p odd is alarming. To one or two of you, there is no need for such language! To the rest of you here goes. © © It is August and volumes in most small caps are thin. Most sensible folks are sitting on a beach. But there has been one persistent seller who has been belting out round number parcels for a few days. He/she is not big enough to be a notifiable holder but that has hit the shares. You then throw in some folk who are bored with a lack of news and then others who are just panicking and selling as the share price slide means something must be wrong. It is not it is just that seller and the bored punters. We expect a raft of announcements within weeks including ones with real names you have heard of and ones that show real revenues being generated. There is no balance sheet issue here to worry about and the company is in great shape. You cannot say if the seller is done and if we are at a low but we know the shares are cheap. And thus for the first time in a couple of years FIML – the company owned by Tom Winnifrith’s family’s trusts – which already owns vast numbers of Optibiotix shares has gone into the market and bought more. The stance is VERY STRONG BUY and we still see these shares being 100p+ far sooner than most folks think..
There must come a point when the difference between the SP and the nominal 25p share price becomes so large that the 'extra fee' that AVO have to pay Bracknor to cover the gap makes it financially useless to convert any more tranches. The last one cost them nearly £200K on a £400K loan and that was at a much higher SP. How much would it cost them today?
..usually means good news
Seems like the SP has woken up - any ideas?
Excuse my ignorance here, but I think someone mentioned that the auditors have to sign off on AVO being a 'going financial concern' this month? Is that true? And what happens if they don't feel able to do that?
Re: Hearing that on the radio makes me absolutely convinced this will be a massive, worldwide breakthrough. Wow Yeah, but the company needs to stay afloat long enough to bring it to market. Hope it manages it, because lots will benefit.
Prospective claim by Slater and Gordon Further to its announcement on 30 November 2016, Watchstone Group plc (LON:WTG) has now received further correspondence from a firm of solicitors acting for Slater and Gordon Limited (ASX: SGH) ("SGH") stating that it intends to issue proceedings by the end of this month. Its letter states that SGH intends to make a claim for a total amount of approximately £600m on the basis that but for fraudulent misrepresentation it would not have entered into the transaction at all. A groundless claim for fraudulent misrepresentation was dismissed by the independent barrister in respect of the warranty escrow process relating to the sale of the Professional Services Division in November 2016 ("Opinion"). The Opinion, which was formed on the basis of evidence provided by both SGH and Watchstone, stated that a misrepresentation claim was not a bona fide claim with a better than 50 per cent prospect of success. Watchstone denies any misrepresentation in the strongest terms and remains satisfied that neither the warranty claim nor a misrepresentation claim have merit and will defend such claims robustly if proceedings are brought. Despite multiple requests, SGH has continuously declined to disclose key evidence in its possession which would be relevant to the merits and quantum of its purported claims. Watchstone believes this evidence will be available to it in the event that SGH issues proceedings and it intends to seek disclosure of such information at the earliest possible opportunity. Watchstone will make further announcements in due course, as appropriate.
Now
... anyone had any luck?
Now showing on share.com
Brycen - it's Ipsos